The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

Pneumonia is a lung infection that annually impacts millions of people around the globe, according to the Centers for Disease ...

Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...

As we are approaching winter and there is an increase in respiratory diseases, it’s also important to know about pneumococcal ...

The dangerous pneumococcal disease can be fatal to babies and children. Picture: CDC Pediatrician and infectious disease researcher Professor Peter Richmond said declining rates of vaccination ...

Rates of invasive pneumococcal disease are at their highest levels since 2004. While more effective vaccines have been approved for use in Australia, most at-risk people can't get them ...

“New generation vaccines need to be rolled out through the National Immunisation Program without further delay. We simply can’t risk not having the best available pneumococcal protection ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

Increasing use of budesonide in IBD and other immunological disorders has encouraged its use in AIH, both for treatment induction and remission maintenance. [57] ...

Corticosteroid therapy is effective in all forms of autoimmune hepatitis, and the combination ... cytokine manipulations, T cell vaccination, oral tolerance, and gene therapy.

Pneumonia can be caused by a virus, bacteria or fungus. Each of these can cause an immune reaction in the tissues of the ...

Prior to COVID-19, pneumococcal vaccines were the largest vaccine market worldwide – estimated at around $8 billion – with Prevnar capturing almost $6 billion of that total in 2020 from its ...